MedTrace Logo

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

NCT06745882 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2026-04-02

No results posted yet for this study

Summary

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

Conditions

Interventions

DRUG

Cisplatin

Given on day 1 of every 21-day cycle.

DRUG

Carboplatin

Given on day 1 of every 21-day cycle.

DRUG

Pemetrexed

Given on day 1 of every 21-day cycle.

DRUG

Pembrolizumab

Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.

DRUG

Abraxane

Given on days 1, 8, and 15 of each 21-day cycle.

DRUG

Paclitaxel

Given on day 1 of every 21-day cycle.

Sponsors & Collaborators

Principal Investigators

  • Jhanelle Gray, MD · Moffitt Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-13
Primary Completion
2030-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745882 on ClinicalTrials.gov